Home > Insider Trading > Filing (0001235802-23-000030)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1427570	Reshape Lifesciences Inc.	RSLS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1181166	Thomas Stankovich	1001 Calle Amanecer San Clemente CA 92673	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.001 Par Value Per Share	Disposition	2023-01-24	48	$7.49	6,461	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-01-24	110	$7.49	6,351	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-02-02	157	$13.29	6,194	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-02-28	103	$4.25	6,091	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.